We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
News From the Food and Drug Administration.
- Authors
Voelker, Rebecca
- Abstract
The article presents several news briefs from the U.S. Food and Drug Administration, including the request for Endo Pharmaceutics Inc. to remove its extended-release opioid Opana ER from the market due to the potential for abuse, the approval of the Sapien 3 transcatheter heart valve for the treatment of aortic stenosis, and the approval of a generic form of the drug atomoxetine for the treatment of attention-deficit hyperactivity disorder.
- Subjects
UNITED States. Food &; Drug Administration; ENDO Pharmaceuticals Inc.; OPIOIDS; PROSTHETIC heart valves; AORTIC stenosis treatment; ATOMOXETINE; TREATMENT of attention-deficit hyperactivity disorder; GENERIC drugs; GOVERNMENT policy; THERAPEUTICS
- Publication
JAMA: Journal of the American Medical Association, 2017, Vol 318, Issue 3, p232
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.2017.8439